A Multicenter, Open Label, Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) (Taliglucerase Alfa) In Pediatric Subjects With Type 1 Gaucher Disease
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 03 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.